Abstract: Pyrimidine compounds of formula (I) shown herein. Also disclosed are pharmaceutical compositions containing one of the pyrimidine compounds and methods of using the pyrimidine compounds to treat or prevent chemotherapy-induced peripheral neuropathy.

Abstract: A method for assessment of neural function by establishing an analysis module is revealed. The first step of the method is to capture images of the cultured cells with a plurality of fluorescence labeling by a fluorescence microscopy system for image analysis. The cultured cells include neurons and non-neuronal cells. Then select neurons with neurites having fluorescence labeling and exclude non-neuronal cells according to an area and a fluorescence intensity of nucleus. Also calculate an area of the neuronal cell body, a length of the neurites and a number of processes and branches to verify outgrowth of the neurites of the neurons. Next calculate a number of synaptic puncta having fluorescence labeling on the area of the neurites having fluorescence labeling defined in Step 2 to verify formation of the synaptic puncta of the neurons for assessment of neural function.

Abstract: Fused bicycle indol, indoline, azoindole, or azoindoline compounds of Formula (I) set forth herein. Also disclosed are pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing the same. Further disclosed is a method for treating cancer, e.g., glioma, prostate cancer, and colorectal cancer, with these compounds.

Abstract: Fused bicycle indol, indoline, azoindole, or azoindoline compounds of Formula (I) set forth herein. Also disclosed are pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing the same. Further disclosed is a method for treating cancer, e.g., glioma, prostate cancer, and colorectal cancer, with these compounds.

Abstract: A method for assessment of neural function by establishing an analysis module is revealed. The first step of the method is to capture images of the cultured cells with a plurality of fluorescence labeling by a fluorescence microscopy system for image analysis. The cultured cells include neurons and non-neuronal cells. Then select neurons with neurites having fluorescence labeling and exclude non-neuronal cells according to an area and a fluorescence intensity of nucleus. Also calculate an area of the neuronal cell body, a length of the neurites and a number of processes and branches to verify outgrowth of the neurites of the neurons. Next calculate a number of synaptic puncta having fluorescence labeling on the area of the neurites having fluorescence labeling defined in Step 2 to verify formation of the synaptic puncta of the neurons for assessment of neural function.

Abstract: Cathepsin S inhibitors having formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune/inflammatory diseases.

Abstract: Aryl substituted sulfonamide compounds of formula (I): wherein bond, X, Y, R1, R2, R3, m, and n are defined herein. Also disclosed is a method for treating cancer with these compounds.

Abstract: Coumarin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, and X are defined herein. Also disclosed is a method for treating cancer with coumarin compounds.

Abstract: A serious of nitro heterocyclic derivatives including a structure of formula (I) are provided. In formula (I), P, Q and R1 to R8 are defined in the specification. The derivatives disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

Abstract: Cathepsin S inhibitors having formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune/inflammatory diseases.

Abstract: Aryl substituted sulfonamide compounds of formula (I): wherein bond, X, Y, R1, R2, R3, m, and n are defined herein. Also disclosed is a method for treating cancer with these compounds.

Abstract: A series of indoline-sulfonamide compounds is disclosed. The formula of indoline-sulfonamide compounds is shown as formula (I). In formula (I), R1 is H or halogen; R2 is Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), or R?—C(O)—, and Ar is a substituted or unsubstituted C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R? and R? independently is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 is C5-C15 aryl or C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

Abstract: Coumarin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, and X are defined herein. Also disclosed is a method for treating cancer with coumarin compounds.

Abstract: Indole compounds of the formula: wherein L1, L2, R1, R2, Ra, Rb, Rc, Rd, and Re are defined herein. Also disclosed are methods of using of the indole compounds in inhibiting tubulin polymerization and treating cancer and other angiogenesis-related disorders.

Abstract: A series of Z-stilbenes derivatives are disclosed, which have the structure as shown by formula 1. In the structure of formula 1, X is hydrogen, NHR, or nitro group, and R is hydrogen. Y and Z is independently hydrogen, halogen, C1-C10 alkyl, or C1-C10 alkoxyl. Furthermore, A is hydrogen, hydroxyl, or amino group. The compounds of the present invention have both aqueous solubility and anti-tumor activity. The Z-stilbenes derivatives of the present invention can further include a pharmaceutical carrier to form pharmaceutical compositions as potent anti-mitotic agents and anti-cancer agents.

Abstract: This invention relates to methods of inhibiting tubulin polymerization and treating cancer and other angiogenesis-related disorders with indole compounds of the formula: wherein L1, L2, R1, R2, Ra, Rb, Rc, Rd, and Re are defined herein.

Abstract: Compounds of the following formula: wherein A, D, Q, T, U, V, W, X, Y, Z, R1, and are as defined herein. This invention also relates to a method of inhibiting tubulin polymerization, or treating cancer or an angiogenesis-related disorder with one of these compounds.

Abstract: A series of Z-stilbenes derivatives are disclosed, which have the structure as shown by formula 1. In the structure of formula 1, X is hydrogen, NHR, or nitro group, and R is hydrogen. Y and Z is independently hydrogen, halogen, C1-C10 alkyl, or C1-C10 alkoxyl. Furthermore, A is hydrogen, hydroxyl, or amino group. The compounds of the present invention have both aqueous solubility and anti-tumor activity. The Z-stilbenes derivatives of the present invention can further include a pharmaceutical carrier to form pharmaceutical compositions as potent anti-mitotic agents and anti-cancer agents.

Abstract: A series of indoline-sulfonamide compounds is disclosed. The formula of indoline-sulfonamide compounds is shown as formula (I). In formula (I), R1 is H or halogen; R2 is Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), or R?—C(O)—, and Ar is a substituted or unsubstituted C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R? and R? independently is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 is C5-C15 aryl or C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

Abstract: Compounds of the following formula: wherein A, D, Q, T, U, V, W, X, Y, Z, R1, and ---- are as defined herein. This invention also relates to a method of inhibiting tubulin polymerization, or treating cancer or an angiogenesis-related disorder with one of these compounds.